Arseus H1 profit beats expectations led by drug ingredients
BRUSSELS Aug 2 (Reuters) - Belgian medical equipment maker Arseus posted better-than-expected core profit in the first half of 2013, led by a surge in profitability at its Fagron unit which sells medical ingredients to pharmacies.
Recurring core profit (REBITDA) rose 29.9 percent in the first-half of 2013 to 50.4 million euros ($66.70 million), it said on Friday. That was better than the 45 million euros expected in a Reuters consensus.
It said that for 2013 it expected healthy organic growth with profitability growing faster than turnover. ($1 = 0.7557 euros) (Reporting by Robert-Jan Bartunek)
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; more snow to blanket East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'